Nova Eye Medical Limited (ASX:EYE) Achieves Record Revenues for FY25
Financial Performance
Nova Eye Medical Limited reported record revenues of A$28.8 million for FY25, marking a 21% increase from FY24. The group’s H2FY25 sales reached A$15.7 million, up 46% on a comparable period.
US Sales Growth
US sales amounted to US$14.2 million, a 25% increase, driven by six consecutive half-years of growth with the iTrack™ Advance. Q4FY25 sales also reached a record A$8.4 million.
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
